跳至主要内容
临床试验/ACTRN12619000066189
ACTRN12619000066189尚未招募未知

Investigating the effect of Endoscopic Sleeve Gastroplasty (ESG) on Non-alcoholic Fatty Liver Disease (NAFLD) and the metabolic syndrome in obese participants

ew Zealand Liver Transplant Unit0 个研究点目标入组 10 人开始时间: 2019年1月17日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
20 Years 至 65 Years(—)
性别
All

入选标准

  • 1. Liver biopsy with NAFLD/NASH (NAS score greater than or equal to 4), (or historic biopsy within 6-months)
  • 2. BMI 30- 45Kg/m2. AND at least one additional metabolic risk factor: (HT, Type II diabetes or dyslipidaemia).
  • 3. Age 20- 65

排除标准

  • Patients with cirrhosis of the liver and/or portal hypertension,
  • Antiplatelet therapy (excluding low dose aspirin),
  • Severe cardiac or respiratory disease, Previous gastric surgery, Hiatus hernia >3cm
  • Inflammatory bowel disease,
  • Pregnancy, or breast feeding.
  • No other liver disease (excluded viral hepatitis, AIH, HFe, alpha-1 AT deficiency),
  • Medications known to cause steatohepatitis.
  • Alcohol consumption: >21U/ week male, >14U/week female
  • Unable to follow dietary guidelines.

研究者

发起方
ew Zealand Liver Transplant Unit

相似试验